Business context and reporting period
Aytu BioPharma, Inc. filed this Form 10-Q for the three and six months ended December 31, 2020, its fiscal second quarter and first half of fiscal 2021—not calendar 2020 Q2. Aytu commercializes prescription and consumer health products. Its portfolio includes primary-care and pediatric prescription products, plus consumer products acquired with Innovus in February 2020. Comparisons with 2019 are materially affected by the pediatric and Innovus acquisitions.
Financial performance and liquidity
| Metric | Three months ended Dec. 31 | Six months ended Dec. 31 |
|---|---|---|
| Revenue, 2020 | $15.1 million | $28.7 million |
| Revenue, 2019 | $3.2 million | $4.6 million |
| Gross profit / gross margin, 2020 | $9.1 million / approximately 60% | $18.8 million / approximately 66% |
| Operating loss, 2020 | $5.6 million | $9.1 million |
| Net loss, 2020 | $9.5 million | $13.8 million |
| Net loss, 2019 | $0.2 million | $5.1 million |
| Operating cash used, 2020 | $10.9 million for six months |
- Revenue rose 377% for the quarter and 521% for the half year, chiefly due to the acquired portfolios and COVID-19 test-kit sales. Consumer Health contributed $7.9 million of quarterly revenue; primary care and devices contributed $4.1 million and pediatrics $3.1 million.
- Quarterly SG&A was $12.9 million, up 97%; cost of sales was $6.0 million. For the half year, SG&A was $24.3 million and cost of sales $9.8 million. Higher expenses reflect the expanded businesses, while R&D growth included Healight development.
- At December 31, cash and cash equivalents were $62.0 million, restricted cash $0.3 million, current assets $92.5 million, and current liabilities $25.8 million. Total assets were $166.7 million and total liabilities $54.0 million.
- Cash used in operations was $10.9 million for six months, versus $9.1 million in the prior-year period. Investing used $0.05 million; financing provided $24.9 million, largely from equity offerings. Cash, cash equivalents and restricted cash ended at $62.3 million.
- The balance sheet reports only $41,000 of debt, but separately includes fixed-payment arrangements, contingent consideration and CVR liabilities. These should not be treated as equivalent to the debt line: fixed-payment arrangements totaled about $11.9 million and current and long-term contingent consideration and CVRs together were about $22.8 million.
Material changes and unusual items
- Net loss increased from $0.2 million to $9.5 million for the quarter. In the prior-year quarter, a $5.2 million gain from derecognizing contingent consideration helped offset operating losses. The current quarter instead included a $3.3 million fair-value loss on contingent consideration and a $0.3 million loss on a debt exchange.
- For the six-month comparison, the $5.2 million prior-year derecognition gain was absent; the 2020 period included $3.3 million of contingent-consideration fair-value losses and $0.9 million of CVR fair-value losses. These valuation changes are non-cash items.
- Aytu raised approximately $29.6 million net during the December quarter through its at-the-market program and a public offering. The December offering issued about 4.8 million shares, alongside warrants. Common shares outstanding increased to 17.9 million from 12.6 million at June 30, 2020. A 1-for-10 reverse stock split took effect December 8; reported share and per-share amounts reflect it.
- The filing says management has sufficient cash to cover expected net cash outflows for the 12 months following filing and sees no substantial doubt about the company’s ability to continue as a going concern. Operations nevertheless continue to consume cash.
Outlook, transactions and risks
- Management expects revenue to grow and operating costs to increase modestly as it integrates acquisitions; it expects cash use to decline over time. No specific revenue, earnings or cash-flow guidance is provided. Management may seek additional capital, with no assurance it will be available on acceptable terms.
- The proposed Neos Therapeutics merger was pending shareholder approvals. As of February 5, 2021, the company estimated approximately 5.4 million shares would be issued, with a fair value of $44.2 million; former Neos holders were expected to own about 24% of the combined company. Management cited potential annualized cost synergies of up to approximately $15 million beginning fiscal 2022; realization is uncertain.
- The filing describes potential Neos debt assumed upon closing, including approximately $30.6 million in the merger discussion, with $15 million due at closing, $0.6 million in April 2021 and $15 million in May 2022. A separate subsequent discussion states Neos debt was $38.3 million as of January 26, 2021. These are different dates/figures and should be reconciled against the merger documents.
- Other risks include acquisition integration, dilution, debt service, dependence on product sales and financing, contingent payments, and regulatory and commercialization uncertainty. Healight remained investigational, with human studies planned. On January 20, 2021, Aytu licensed MiOXSYS commercialization to Avrio Genetics in return for royalties and minimum annual payments; Aytu expected to transfer related expenses to Avrio.
- Legal matters disclosed include a settled advertising-claims matter with a $150,000 civil penalty, $11,500 investigative-cost reimbursement and $43,000 restitution, subject to court approval; Hikma-related product supply obligations; and previously dismissed shareholder lawsuits with mootness-fee claims reserved but none filed to date.
Important facts for investors to verify
- How much revenue and gross profit are recurring across acquired portfolios, and how much came from COVID-19 test sales?
- Whether cash burn improves as management forecasts, including the effects of working capital and ongoing fixed-payment obligations.
- The full schedule and terms of fixed payments, contingent consideration, CVRs, product minimums and royalties, beyond the balance-sheet debt figure.
- Final Neos merger terms, debt at closing, required repayment or refinancing, share issuance and dilution, and evidence supporting projected synergies.
- Whether the filing’s differing Neos debt figures and its wording on cash-flow comparison periods reconcile to the underlying statements and merger disclosures.